Isofol Medical has announced that Solasia Pharma, its development and commercialisation partner in Japan, intends to invest c SEK140m to support planned Phase II and III trials of arfolitixorin in the region, and the subsequent regulatory submission process for the candidate in metastatic colorectal ...Den vollständigen Artikel lesen ...
© 2025 Edison Investment Research